IDEXX Laboratories Inc (IDXX)vsMainz Biomed BV (MYNZ)
IDXX
IDEXX Laboratories Inc
$562.16
-0.46%
HEALTHCARE · Cap: $44.24B
MYNZ
Mainz Biomed BV
$2.46
+0.41%
HEALTHCARE · Cap: $7.90M
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 673612% more annual revenue ($4.45B vs $659,940). IDXX leads profitability with a 24.6% profit margin vs 0.0%. IDXX earns a higher WallStSmart Score of 63/100 (C+).
IDXX
Buy63
out of 100
Grade: C+
MYNZ
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.1%
Fair Value
$423.77
Current Price
$562.16
$138.39 premium
Intrinsic value data unavailable for MYNZ.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 70 in profit
Strong operational efficiency at 31.8%
Safe zone — low bankruptcy risk
Keeps 25 of every $100 in revenue as profit
No standout strengths identified
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 28.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 24.6% and operating margin at 31.8%. Revenue growth of 14.3% demonstrates continued momentum.
Bull Case : MYNZ
MYNZ has a balanced fundamental profile.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 41.3x leaves little room for execution misses.
Bear Case : MYNZ
The primary concerns for MYNZ are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
IDXX profiles as a mature stock while MYNZ is a value play — different risk/reward profiles.
IDXX carries more volatility with a beta of 1.54 — expect wider price swings.
IDXX is growing revenue faster at 14.3% — sustainability is the question.
IDXX generates stronger free cash flow (234M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (63/100 vs 18/100), backed by strong 24.6% margins and 14.3% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Mainz Biomed BV
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Mainz Biomed BV is an innovative biotechnology company specializing in the development of advanced diagnostic solutions for early cancer detection, with a particular emphasis on gastrointestinal disorders. The company's flagship product, a proprietary non-invasive colorectal cancer screening test, employs state-of-the-art biomarker technology to improve the accuracy and accessibility of screenings. As a key player in the rapidly expanding diagnostics market, Mainz Biomed is dedicated to meeting critical clinical needs and enhancing patient outcomes. With a strong intellectual property position and a focus on research and development, the company is poised to capitalize on the increasing global demand for effective cancer diagnostic tools.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?